MX2023008971A - Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1. - Google Patents

Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1.

Info

Publication number
MX2023008971A
MX2023008971A MX2023008971A MX2023008971A MX2023008971A MX 2023008971 A MX2023008971 A MX 2023008971A MX 2023008971 A MX2023008971 A MX 2023008971A MX 2023008971 A MX2023008971 A MX 2023008971A MX 2023008971 A MX2023008971 A MX 2023008971A
Authority
MX
Mexico
Prior art keywords
methods
administering
materials
monitoring cancer
mcl
Prior art date
Application number
MX2023008971A
Other languages
English (en)
Inventor
Agnieszka Kielczewska
Brian Chan
Michael C Boyle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023008971A publication Critical patent/MX2023008971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgación proporciona anticuerpos anti-Mcl-1 de cualquier forma, y fragmentos de los mismos, que se unen al antígeno con una unión inesperadamente alta a Mcl-1, proporcionando herramientas útiles en métodos de seguimiento de células cancerosas que expresan Mcl-1 y métodos de tratamiento de cánceres, particularmente cánceres sanguíneos, que comprenden dichas células cancerosas.
MX2023008971A 2021-01-29 2022-01-28 Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1. MX2023008971A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163143682P 2021-01-29 2021-01-29
PCT/US2022/014401 WO2022165240A1 (en) 2021-01-29 2022-01-28 Materials and methods for monitoring cancer by administering an anti-mcl1 antibody

Publications (1)

Publication Number Publication Date
MX2023008971A true MX2023008971A (es) 2023-08-15

Family

ID=82654972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008971A MX2023008971A (es) 2021-01-29 2022-01-28 Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1.

Country Status (14)

Country Link
US (1) US20240117069A1 (es)
EP (1) EP4284826A1 (es)
JP (1) JP2024508222A (es)
KR (1) KR20230135087A (es)
CN (1) CN116806156A (es)
AU (1) AU2022214936A1 (es)
CA (1) CA3203780A1 (es)
CL (1) CL2023002189A1 (es)
CO (1) CO2023009810A2 (es)
CR (1) CR20230388A (es)
IL (1) IL303844A (es)
MX (1) MX2023008971A (es)
PE (1) PE20231731A1 (es)
WO (1) WO2022165240A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086321A1 (en) * 1993-02-02 2002-07-04 Craig Ruth W. Myeloid cell leukemia associated gene MCL-1
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
NZ597767A (en) * 2007-05-21 2013-06-28 Bristol Myers Squibb Co Antibodies to IL-6 and use thereof
BR112016015589A2 (pt) * 2014-01-06 2017-10-31 Hoffmann La Roche módulos de trânsito monovalentes para a barreira hematoencefálica
US20200399373A1 (en) * 2018-02-14 2020-12-24 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule and combination
JP7205691B2 (ja) * 2019-01-23 2023-01-17 ウシオ電機株式会社 抗イヌプロカルシトニン抗体及びこれを用いた検査用キット

Also Published As

Publication number Publication date
AU2022214936A1 (en) 2023-06-29
CR20230388A (es) 2023-10-05
CO2023009810A2 (es) 2023-08-09
KR20230135087A (ko) 2023-09-22
JP2024508222A (ja) 2024-02-26
IL303844A (en) 2023-08-01
WO2022165240A1 (en) 2022-08-04
CA3203780A1 (en) 2022-08-04
US20240117069A1 (en) 2024-04-11
CL2023002189A1 (es) 2024-03-01
AU2022214936A9 (en) 2023-08-17
PE20231731A1 (es) 2023-10-26
CN116806156A (zh) 2023-09-26
EP4284826A1 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
PH12020552221A1 (en) Anti-pd-1 antibodies and uses thereof
CR20200467A (es) Agentes anticuerpos anti-cd25
JOP20200292A1 (ar) Bcma / cd3 و gprdc5d / cd3 مضادات غير محددة للاستخدام في علاج السرطان
MX2022009947A (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos.
PH12020500368A1 (en) B7-h4 antibodies and methods of use thereof
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
TN2019000159A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
BR112019005697A2 (pt) anticorpos anti-muc16-cd3 biespecíficos e conjugados de fármaco e anti-muc16
NZ767596A (en) Antibodies that bind cd39 and uses thereof
JOP20190236A1 (ar) أجسام مضادة لـ ilt4 وشظايا ارتباط بمولد ضد
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
MX2022000325A (es) Anticuerpos dirigidos contra dll3 y usos de los mismos.
MX2021004226A (es) Terapia combinada contra el cáncer.
MX2020008730A (es) Regímenes de dosificación de anticuerpo b7-h4.
ZA202008095B (en) Humanized antibodies against psma
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
CO2023017609A2 (es) Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso
PH12020551451A1 (en) Anti-cd25 for tumour specific cell depletion
MX2023008971A (es) Materiales y metodos para el seguimiento del cancer mediante la administracion de un anticuerpo anti-mcl1.
MX2022011178A (es) Composiciones y metodos para inmunoterapia contra cancer positivo para npm1c.
MX2021012652A (es) Metodos para el tratamiento de sujetos con artritis psoriasica.